Rep. Robert Bresnahan, Jr. Sells Charles River Laboratories International, Inc. (NYSE:CRL) Shares

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Charles River Laboratories International, Inc. NYSE: CRL. In a filing disclosed on May 31st, the Representative disclosed that they had sold between $1,001 and $15,000 in Charles River Laboratories International stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
• Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
• Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
• Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL traded up $4.83 during mid-day trading on Wednesday, hitting $143.32. The company had a trading volume of 849,402 shares, compared to its average volume of 1,459,202. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The stock has a market cap of $7.04 billion, a price-to-earnings ratio of 955.47, a PEG ratio of 4.54 and a beta of 1.48. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The firm's 50 day simple moving average is $128.17 and its two-hundred day simple moving average is $159.66.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. During the same period last year, the firm posted $2.27 EPS. Charles River Laboratories International's quarterly revenue was down 2.7% compared to the same quarter last year. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on CRL shares. Barclays lifted their target price on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research note on Thursday, May 8th. Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research report on Wednesday, May 14th. Morgan Stanley dropped their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and an average price target of $171.85.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company's stock.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently modified their holdings of the stock. First Hawaiian Bank lifted its stake in Charles River Laboratories International by 13.9% during the first quarter. First Hawaiian Bank now owns 5,096 shares of the medical research company's stock valued at $767,000 after buying an additional 620 shares in the last quarter. IFM Investors Pty Ltd lifted its position in shares of Charles River Laboratories International by 8.7% in the 1st quarter. IFM Investors Pty Ltd now owns 9,385 shares of the medical research company's stock valued at $1,413,000 after acquiring an additional 755 shares in the last quarter. Empowered Funds LLC acquired a new position in Charles River Laboratories International in the 1st quarter worth approximately $418,000. MBB Public Markets I LLC purchased a new position in Charles River Laboratories International during the 1st quarter worth approximately $284,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Charles River Laboratories International by 407.0% during the first quarter. Goldman Sachs Group Inc. now owns 997,488 shares of the medical research company's stock valued at $150,142,000 after buying an additional 800,762 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).